BISCAY D2615C00001: An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY)

February 18, 2019
https://clinicaltrials.gov/ct2/results?id=NCT02546661
Cancer - Genitourinary/ Bladder, Cancer - Genitourinary/ Bladder/ Prostate/ Urothel
Principal Investigator: Ding Wang, MD
Cancer, Bladder Cancer, Bladder, Muscle, Muscle Invasive, Phase 1, Phase I, Muscle Invasive Bladder Cancer, MIBC, BISCAY
Open